Summary:
In patients with chronic coronary artery disease (CAD), oral beetroot capsule supplementation significantly improved serum omega-3 fatty acids, decreased pro-oxidant markers like total oxidant status (TOS) and myeloperoxidase (MPO), and modulated fatty acid ratios (SFAs/PUFAs and PA/OA) compared to placebo and standard treatment over four weeks, though it was associated with no reported adverse effects in this analysis.
| PICO | Description |
|---|---|
| Population | Adults (both male and female) with chronic coronary artery disease (CAD), participating in a randomized controlled trial over a 4-week period. |
| Intervention | Supplementation with beetroot capsules alone or in combination with vitamin C. |
| Comparison | Placebo/control group receiving standard care, without beetroot supplementation. |
| Outcome | Significant increases in docosahexaenoic acid (DHA), omega-3, and EPA+DHA serum levels. Significant reductions in saturated to polyunsaturated fatty acid ratio (SFAs/PUFAs), palmitic to oleic acid ratio (PA/OA), total oxidant status (TOS), and myeloperoxidase (MPO), indicating improved lipid profile and reduced oxidative stress. No adverse events were reported in this analysis. |
Source: Mansouri-Baseri, Amirhossein, et al. “Effect of Beetroot Extract Supplementation on Serum Fatty Acid Profiles and Oxidative Stress Markers in Chronic Coronary Artery Disease Patients: A Secondary Analysis of a Randomized Controlled Trial.” Read article here.
